People with Lynch syndrome face a much higher lifetime risk of developing colorectal cancer and several other cancers. Current prevention strategies rely heavily on regular screenings, surveillance, and in some cases preventive surgery. A new study suggests that a cancer-prevention vaccine may one day become another tool for reducing that risk.
Researchers tested an experimental vaccine called Nous-209 in adults with Lynch syndrome and found that it generated strong, long-lasting immune responses against cancer-related targets while maintaining a favorable safety profile.
What Is Lynch Syndrome?
Lynch syndrome is one of the most common inherited cancer syndromes, affecting about 1 in 300 people. It is caused by inherited mutations in genes responsible for repairing damaged DNA. When these repair systems fail, mutations can accumulate and increase the risk of colorectal cancer, endometrial cancer, and several other cancers.
Because these DNA repair defects create abnormal proteins that are not normally found in healthy cells, researchers have explored whether the immune system can be trained to recognize and attack these abnormal targets before cancer develops.
How the Vaccine Works
Nous-209 is designed to target more than 200 shared cancer-related protein fragments known as frameshift peptides. These proteins are commonly found in tumors associated with Lynch syndrome and other cancers with microsatellite instability. Rather than being personalized for each patient, the vaccine is an “off-the-shelf” product intended for use in a broad population of people with Lynch syndrome.
The vaccine is delivered in two stages: an initial priming dose followed by a booster dose eight weeks later. Researchers hoped this approach would stimulate a broad and durable immune response capable of identifying and eliminating precancerous cells before they progress to cancer.
Strong Immune Responses in Every Evaluable Participant
The phase 1b/2 study enrolled 45 adults with Lynch syndrome who had no active cancer at the time of enrollment. The main goals were to evaluate safety and determine whether the vaccine could generate a meaningful immune response.
Among the 37 participants who could be fully evaluated for immune responses, every participant developed vaccine-specific T-cell responses after vaccination. Researchers observed particularly strong activity, with immune responses peaking at approximately 1,100 interferon-gamma spot-forming cells per million immune cells.
The response also appeared durable. Positive immune activity remained detectable in 97% of participants six months after vaccination and in 85% one year later.
Safety Results Were Encouraging
Nearly all participants experienced some side effects, but most were mild and temporary. The most common reactions included injection-site discomfort, fatigue, muscle aches, headaches, and fever-like symptoms. No treatment-related serious adverse events were reported.
When more severe reactions occurred, they generally lasted only a few days, resolved completely, and did not require hospitalization. All participants who experienced these reactions were still able to receive their scheduled booster dose.
Early Signs of Cancer Prevention Potential
Although the trial was not designed to prove that the vaccine prevents cancer, researchers reported several findings that support further investigation.
The vaccine generated immune responses against many targets that are also found in colorectal precancers and cancers associated with Lynch syndrome. More than 80% of the vaccine targets identified as immunogenic in the study were also found in independent samples of Lynch syndrome precancers and cancers.
Researchers also found evidence that vaccine-induced immune cells could directly kill cancer cells in laboratory experiments.
At follow-up colonoscopies, no participants were found to have advanced adenomas or colorectal cancer. While the study was too small to determine whether the vaccine truly reduced cancer risk, investigators considered these findings encouraging and worthy of larger trials.
What Comes Next?
The researchers emphasize that larger randomized studies will be needed to determine whether Nous-209 can actually reduce cancer incidence in people with Lynch syndrome. However, the current results provide important proof of concept that a preventive cancer vaccine can safely generate strong and lasting immune responses against cancer-associated targets in this high-risk population.
If future trials confirm these findings, vaccines such as Nous-209 could represent a new approach to cancer prevention—helping the immune system stop cancer before it starts.
Source:
D’Alise AM, Willis J, Duzagac F, et al. Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial. Nature Medicine. 2026;32:1002–1011. doi:10.1038/s41591-025-04182-9.
